OKYO Pharma Management
Management criteria checks 1/4
OKYO Pharma's CEO is Gary Jacob, appointed in Jan 2021, has a tenure of 2.58 years. total yearly compensation is £1.53M, comprised of 17.5% salary and 82.5% bonuses, including company stock and options. directly owns 3.18% of the company’s shares, worth €1.04M. The average tenure of the management team and the board of directors is 2.6 years and 2.6 years respectively.
Key information
Gary Jacob
Chief executive officer
UK£1.5m
Total compensation
| CEO salary percentage | 17.5% |
| CEO tenure | 2.6yrs |
| CEO ownership | 3.2% |
| Management average tenure | 2.6yrs |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -UK£7m |
| Jun 30 2022 | n/a | n/a | -UK£5m |
| Mar 31 2022 | UK£2m | UK£266k | -UK£4m |
| Dec 31 2021 | n/a | n/a | -UK£4m |
| Sep 30 2021 | n/a | n/a | -UK£4m |
| Jun 30 2021 | n/a | n/a | -UK£3m |
| Mar 31 2021 | UK£633k | UK£62k | -UK£3m |
Compensation vs Market: Gary's total compensation ($USD1.95M) is above average for companies of similar size in the German market ($USD418.12K).
Compensation vs Earnings: Gary's compensation has increased whilst the company is unprofitable.
CEO
Gary Jacob (76 yo)
2.6yrs
Tenure
UK£1,525,565
Compensation
Dr. Gary S. Jacob, PhD, served as an Independent Director at Virpax Pharmaceuticals, Inc. since April 2020 until July 25, 2022. He had been an Independent Director of Cardiff Oncology, Inc. since February...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.6yrs | UK£1.53m | 3.18% € 1.0m | |
| Founder | no data | no data | no data | |
| Chief Financial Officer | 3yrs | no data | 0% € 0 | |
| Chief Scientific Officer | 2.4yrs | no data | 0% € 0 |
2.6yrs
Average Tenure
65yo
Average Age
Experienced Management: OK11's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.6yrs | UK£1.53m | 3.18% € 1.0m | |
| Independent Non-Executive Director | 1.7yrs | UK£14.46k | 0% € 0 | |
| Non-Executive Chairman | 2.6yrs | UK£124.85k | 57.47% € 18.8m | |
| Independent Non-Executive Director | 3.2yrs | UK£47.20k | 0% € 0 | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Senior Independent Non-Executive Director | 7.8yrs | UK£34.26k | 0.018% € 6.1k | |
| Member of Scientific Advisory Board | 3yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
2.6yrs
Average Tenure
72yo
Average Age
Experienced Board: OK11's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.